Advancing Precision Medicine in Psychiatry
Waveform Biosciences is developing EEG and AI-based technology to predict treatment response and improve the development of novel therapies for serious mental illness.
OUR MISSION
Help researchers identify patients more likely to respond to novel therapies
Very few novel medications for serious mental illnesses (SMIs) have been FDA-approved in the last 50+ years. Research suggests that conditions including schizophrenia, bipolar disorder, and autism spectrum disorder (ASD) arise from complex genetics, meaning a single diagnosis can encompass biologically distinct conditions. Because Phase-3 trials include all patients with a diagnosis, a drug’s efficacy may be obscured in the subgroup of responders. Our technology aims to identify responders before trials, helping these treatments succeed.
OUR APPROACH
Using EEG biomarkers to predict treatment response
EEG can reveal patterns of cortical dysfunction associated with serious mental illness. Rather than linking these patterns to genetic risk, we take a more direct approach: matching baseline EEG signatures to treatment response in Phase-2 clinical trials. AI enables us to identify these predictive patterns across the large volumes of data generated by multi-lead EEG recordings.
1. Baseline EEG
We capture a patient’s brain activity before treatment begins.
2. AI pattern recognition
Our AI identifies EEG signatures associated with response.
3. Response prediction
We identify patients most likely to benefit from treatment.
ABOUT US
Collaboration across disciplines
Waveform Biosciences brings together complementary perspectives across neuropsychiatry, electrophysiology, clinical research, and machine learning to advance precision in psychiatric drug development.
We want to hear from you
For research collaborations, partnerships, or general inquiries, get in touch with the Waveform Biosciences team.